Other Events ·
AstraZeneca reported positive high-level results from the SANOVO Phase III trial, demonstrating that Tagrisso…
AZNAstrazeneca PLC
AstraZeneca reported positive high-level results from the SANOVO Phase III trial, demonstrating that Tagrisso (osimertinib) plus Orpathys (savolitinib) significantly improved progression-free survival versus Tagrisso alone in treatment-naïve patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer and MET overexpression. The combination also showed encouraging overall survival benefits, reinforcing the all-oral regimen's clinical value across high MET and intention-to-treat populations. This builds on prior successes from the SAFFRON and SACHI trials, validating the strategy to intercept MET-driven resistance in first-line settings. AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines.